HUTCHMED (China) (HCM) Non-Current Deferred Tax Liability (2014 - 2025)
HUTCHMED (China)'s (HCM) quarterly Non-Current Deferred Tax Liability came in at $255000.0 in Q4 2025, down 91.47% year-on-year from $3.0 million in Q4 2024, and down 91.47% on a QoQ basis from $3.0 million in Q4 2024.
HUTCHMED (China) (HCM) Non-Current Deferred Tax Liability (2014 - 2025) Analysis & Trends
HUTCHMED (China) (HCM) has 12 years of Non-Current Deferred Tax Liability data on file, last reported at $255000.0 in Q4 2025.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 91.47% year-over-year to $255000.0 in Q4 2025; TTM through Dec 2025 was $255000.0, a 91.47% decrease from a year earlier, with the FY2025 full-year figure at $255000.0, down 91.47% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at $255000.0, down from $3.0 million in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for HCM reached as high as $3.0 million in Q4 2024 and fell as low as $255000.0 in Q4 2025.
- Historically, Non-Current Deferred Tax Liability has averaged $2.0 million across 5 years, with a median of $2.7 million in 2022.
- Across the five-year window, Non-Current Deferred Tax Liability soared 101.48% in 2024 and plunged 91.47% in 2025, its largest moves.
- Year by year, Non-Current Deferred Tax Liability stood at $2.8 million in 2021, then fell by 1.99% to $2.7 million in 2022, then sank by 45.24% to $1.5 million in 2023, then surged by 101.48% to $3.0 million in 2024, then plunged by 91.47% to $255000.0 in 2025.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $255000.0 in Q4 2025, $3.0 million in Q4 2024, and $1.5 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | HUTCHMED (China) | 241.90 Mn | 243.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 255,000.00 |
| Dec 31, 2025 | 255,000.00 |
| Dec 31, 2024 | 2.99 Mn |
| Dec 31, 2024 | 2.99 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Dec 31, 2023 | 1.48 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Dec 31, 2021 | 2.77 Mn |
| Dec 31, 2021 | 2.77 Mn |
| Dec 31, 2020 | 3.55 Mn |
| Dec 31, 2020 | 3.55 Mn |
| Dec 31, 2019 | 2.34 Mn |
| Dec 31, 2019 | 2.34 Mn |
| Dec 31, 2018 | 4.26 Mn |
| Dec 31, 2018 | 4.26 Mn |
| Dec 31, 2017 | 3.82 Mn |
| Dec 31, 2017 | 3.82 Mn |
| Dec 31, 2016 | 4.99 Mn |
| Dec 31, 2016 | 4.99 Mn |